Jubilant Pharmova Limited has announced an earnings webinar to discuss its financial performance for the financial year 2025-26. The pharmaceutical company informed BSE Limited and National Stock Exchange of India Limited about the upcoming investor engagement event under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Webinar Schedule and Details

The earnings webinar has been scheduled with specific timing to accommodate global investors across different time zones.

Registration and Participation Guidelines

The company has established specific protocols for investor participation in the virtual earnings call. Pre-registration is mandatory and must be completed up to 3 hours before the webinar commencement. Participants need to download the latest Zoom application for their respective devices to ensure smooth connectivity.

The webinar format will begin with management commentary on the financial performance for the financial year ended March 31, 2026, followed by an interactive Q&A session. During the question-and-answer segment, participants can join the queue by clicking the "Raise Hand" icon or submit questions through the chat function.

Regulatory Compliance and Documentation

In accordance with regulatory requirements, Jubilant Pharmova will submit the presentation materials to stock exchanges before the event. The presentation will also be hosted on the company's official website at www.jubilantpharmova.com for broader accessibility.

The formal intimation was signed by Naresh Kapoor, Company Secretary, on April 24, 2026, ensuring compliance with disclosure obligations. This structured approach demonstrates the company's commitment to transparent investor communication and regulatory adherence.

Company Background

Jubilant Pharmova Limited operates as a global pharmaceutical company with diverse business segments including Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses. The company maintains a network of 45 radiopharmacies in the US and operates multiple manufacturing facilities serving regulated markets including USA, Europe and other geographies, with approximately 5,500 employees worldwide.

Jubilant Pharmova Limited has submitted its quarterly compliance certificate under SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company filed the mandatory certificate with stock exchanges on April 1, 2026, demonstrating adherence to regulatory requirements for depositories and participants.

Regulatory Compliance Filing

The certificate was filed under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, and submitted to both major Indian stock exchanges. Company Secretary Naresh Kapoor signed and submitted the documentation on behalf of Jubilant Pharmova Limited.

Registrar Confirmation

M/s Alankit Assignments Limited, serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate. General Manager Kamal Garg signed the certificate on behalf of Alankit Assignments Limited, providing the required regulatory confirmation.

The registrar's certificate confirms two critical compliance aspects:

• Securities comprised in the certificates have been properly listed on stock exchanges
• Physical certificates have been duly verified, mutilated, cancelled, and depository names substituted as registered owners

Depository Notifications

The filing was also copied to both major depositories in India to ensure comprehensive regulatory compliance. The notifications were sent to National Securities Depository Limited at Trade World, Lower Parel, Mumbai, and Central Depository Services (India) Limited at Marathon Futurex, Lower Parel, Mumbai.

Corporate Information

Jubilant Pharmova Limited operates as part of the Jubilant Bhartia Company group, with its registered office located at Bhartiagram, Gajraula, District Amroha, Uttar Pradesh. The company maintains its corporate identification number as L24116UP1978PLC004624, reflecting its incorporation history and regulatory status.